35.50
price down icon2.47%   -0.90
after-market アフターアワーズ: 35.50
loading
前日終値:
$36.40
開ける:
$36.37
24時間の取引高:
479.82K
Relative Volume:
0.44
時価総額:
$3.42B
収益:
$225.27M
当期純損益:
$-140.06M
株価収益率:
-22.22
EPS:
-1.5974
ネットキャッシュフロー:
$-87.93M
1週間 パフォーマンス:
+0.28%
1か月 パフォーマンス:
-4.75%
6か月 パフォーマンス:
+10.28%
1年 パフォーマンス:
+45.79%
1日の値動き範囲:
Value
$35.29
$36.63
1週間の範囲:
Value
$35.17
$37.06
52週間の値動き範囲:
Value
$22.09
$40.58

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1079)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
145
Name
Twitter
Name
次回の収益日
2026-08-04
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IDYA icon
IDYA
Ideaya Biosciences Inc
35.50 3.54B 225.27M -140.06M -87.93M -1.5974
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-11-24 開始されました Truist Buy
2025-09-18 開始されました Guggenheim Buy
2025-09-04 開始されました Barclays Overweight
2025-09-04 開始されました Citizens JMP Mkt Outperform
2025-07-22 開始されました TD Cowen Buy
2025-07-10 再開されました Goldman Neutral
2025-06-26 開始されました Wells Fargo Overweight
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
Jul 27, 2026

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo

Jul 27, 2026
pulisher
Jul 27, 2026

IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire

Jul 27, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

IDEAYA Biosciences Inc (IDYA) Balance Sheet - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

IDYA|IDEAYA Biosciences Inc|Price:35.400|Chg%:-0.830 - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

IDYA|IDEAYA Biosciences Inc|Price:36.030|Chg%:-0.200 - TradingKey

Jul 23, 2026
pulisher
Jul 22, 2026

ETFs Investing in IDEAYA Biosciences, Inc. Stocks - TradingView

Jul 22, 2026
pulisher
Jul 21, 2026

IDEAYA Biosciences (IDYA) Stock Analysis: Exploring A 47.49% Upside Potential - DirectorsTalk Interviews

Jul 21, 2026
pulisher
Jul 20, 2026

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus

Jul 20, 2026
pulisher
Jul 19, 2026

How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily

Jul 19, 2026
pulisher
Jul 17, 2026

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - BioSpace

Jul 17, 2026
pulisher
Jul 17, 2026

IDEAYA Biosciences to present new clinical tria... - Pluang

Jul 17, 2026
pulisher
Jul 09, 2026

Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com

Jul 09, 2026
pulisher
Jul 09, 2026

Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com - Investing.com Nigeria

Jul 09, 2026
pulisher
Jul 09, 2026

Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026
pulisher
Jul 09, 2026

Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing - Moomoo

Jul 09, 2026
pulisher
Jul 09, 2026

IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan

Jul 09, 2026
pulisher
Jul 08, 2026

Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer - Ad-hoc-news.de

Jul 08, 2026
pulisher
Jul 07, 2026

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - AOL.com

Jul 07, 2026
pulisher
Jul 07, 2026

Form 144 IDEAYA Biosciences For: 7 July By Investing.com - Investing.com South Africa

Jul 07, 2026
pulisher
Jul 07, 2026

[144] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan

Jul 07, 2026
pulisher
Jul 07, 2026

Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63 - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48 - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus

Jul 07, 2026
pulisher
Jul 07, 2026

RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating - Moomoo

Jul 07, 2026
pulisher
Jul 06, 2026

Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa

Jul 06, 2026
pulisher
Jul 06, 2026

Ideaya Biosciences stock hits 52-week high at $39.28 - Investing.com

Jul 06, 2026
pulisher
Jul 03, 2026

How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st

Jul 03, 2026
pulisher
Jun 29, 2026

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to earnings forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView

Jun 28, 2026

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ideaya Biosciences Inc (IDYA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ruiz Briseno Andres
Chief Accounting Officer
Jul 07 '26
Sale
40.01
9,550
382,131
26,466
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):